CNS Pharmaceuticals, Inc. Schedule 13G/A amendment discloses that Stonepine-affiliated reporting persons beneficially own 159,790 shares of Common Stock, representing 9.9% of the class. The reporting persons state these holdings consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares, and the percentage is calculated using 1,461,449 shares outstanding as of May 13, 2026.
The filing lists shared voting and dispositive power over 159,790 shares across Stonepine Capital Management, the Partnership, Stonepine GP and Jon M. Plexico. The Partnership holds the Common Stock for the benefit of its investors, and the reporting persons disclaim group membership and broader beneficial ownership beyond their pecuniary interest.
Positive
None.
Negative
None.
Insights
Stonepine group reports a nearly 10% position through warrants and shares.
The filing transparently quantifies a 9.9% beneficial ownership position measured on May 13, 2026, combining 21,738 shares and warrants for 1,304,348 shares. Shared voting and dispositive power over 159,790 shares is disclosed across the adviser, GP, partnership and control person.
Potential follow-ups include whether warrants are exercisable and any ownership cap effects; subsequent filings may clarify exercise conditions and timing.
Key Figures
Beneficially owned shares:159,790 sharesPercent of class:9.9%Shares outstanding:1,461,449 shares+2 more
5 metrics
Beneficially owned shares159,790 sharesAmount beneficially owned by each reporting person
Percent of class9.9%Percent of Common Stock based on shares outstanding
Shares outstanding1,461,449 sharesShares outstanding as of <date>May 13, 2026</date>
Common stock held21,738 sharesComponent of reported holdings (explicit shares)
Warrants referenced1,304,348 warrantsWarrants to purchase Common Stock included in holdings
"subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared dispositive powerfinancial
"Shared Dispositive Power 159,790.00"
Schedule 13G/Aregulatory
"SCHEDULE 13G/A"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
CNS Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
18978H508
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
18978H508
1
Names of Reporting Persons
Stonepine Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
159,790.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
159,790.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
159,790.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
18978H508
1
Names of Reporting Persons
Stonepine Capital, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
159,790.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
159,790.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
159,790.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
18978H508
1
Names of Reporting Persons
Stonepine GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
159,790.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
159,790.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
159,790.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
18978H508
1
Names of Reporting Persons
Jon M. Plexico
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
159,790.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
159,790.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
159,790.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The shares of the Common Stock reported herein consist of 21,738 shares of Common Stock and warrants to purchase 1,304,348 shares of Common Stock, subject to a 9.99% beneficial ownership limitation, held by the Reporting Persons as of the date of this report. Percentage calculated based on 1,461,449 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CNS Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
2100 West Loop South, Suite 900, Houston, TX 77027
Item 2.
(a)
Name of person filing:
Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine")
Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership")
Stonepine GP, LLC, a Delaware limited liability company (the "General Partner")
Jon M. Plexico
Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Ordinary Shares except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Ordinary Shares covered by this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703
(c)
Citizenship:
See Item 4 of the cover sheet for each reporting person.
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
18978H508
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Stonepine: 159,790
Partnership: 159,790
General Partner: 159,790
Jon M. Plexico: 159,790
(b)
Percent of class:
Stonepine: 9.9%
Partnership: 9.9%
General Partner: 9.9%
Jon M. Plexico: 9.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Stonepine: 0
Partnership: 0
General Partner: 0
Jon M. Plexico: 0
(ii) Shared power to vote or to direct the vote:
Stonepine: 159,790
Partnership: 159,790
General Partner: 159,790
Jon M. Plexico: 159,790
(iii) Sole power to dispose or to direct the disposition of:
Stonepine: 0
Partnership: 0
General Partner: 0
Jon M. Plexico: 0
(iv) Shared power to dispose or to direct the disposition of:
Stonepine: 159,790
Partnership: 159,790
General Partner: 159,790
Jon M. Plexico: 159,790
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Stonepine Capital Management, LLC
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member
Date:
05/15/2026
Stonepine Capital, L.P.
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member of the General Partner, Stonepine GP, LLC
Date:
05/15/2026
Stonepine GP, LLC
Signature:
/s/ Jon M. Plexico
Name/Title:
Managing Member
Date:
05/15/2026
Jon M. Plexico
Signature:
/s/ Jon M. Plexico
Name/Title:
Reporting person
Date:
05/15/2026
Exhibit Information
EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G
What stake does Stonepine report in CNS Pharmaceuticals (CNSP)?
Stonepine-affiliated filers report beneficial ownership of 159,790 shares, equal to 9.9% of the class, using 1,461,449 shares outstanding as of May 13, 2026.
How is the reported 9.9% position composed?
The filing states the position includes 21,738 shares of Common Stock plus warrants to purchase 1,304,348 shares, subject to a 9.99% beneficial ownership limitation.
Who are the named reporting persons on the Schedule 13G/A?
The filers are Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico, with Mr. Plexico as control person.
Does the Partnership hold the shares for others?
Yes. The Partnership holds the Common Stock for the benefit of its investors and has the right to receive dividends or sale proceeds, per the filing's Item 6 disclosure.
What voting and disposition powers are reported?
Each reporting person discloses 0 sole voting/dispositive power and shared voting and shared dispositive power over 159,790 shares.
